Personalized immune cells target Tough-to-Treat lymphoma
NCT ID NCT03590574
Summary
This study tested a personalized cell therapy called AUTO4 for adults with specific types of T-cell lymphoma that had returned or stopped responding to standard treatments. Doctors collected a patient's own immune cells, engineered them in a lab to better target the cancer, and then infused them back into the patient. The main goals were to see if the treatment was safe and if it could shrink or eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
-
Manchester Royal Infirmary Hospital
Manchester, United Kingdom
-
Queen Elizabeth University Hospital
Glasgow, United Kingdom
-
University College London Hospitals NHS Foundation Trust
London, United Kingdom
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.